Pyridazinedione-based heterobicyclic covalent linkers and methods and applications thereof
US-2024425465-A1 · Dec 26, 2024 · US
Methods for treating epithelian mesenchymal transition related diseases
US10292986B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10292986-B2 |
| Application number | US-201615144286-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 2, 2016 |
| Priority date | May 1, 2015 |
| Publication date | May 21, 2019 |
| Grant date | May 21, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Certain embodiments are directed to methods of treating chronic lung diseases in a subject comprising administering to a subject diagnosed with, exhibiting symptoms of, or at risk of developing a chronic lung disease a therapeutically effective amount of a BRD4 inhibitor or a CDK9 inhibitor to the subject.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating epithelial-mesenchymal transition (EMT) lung fibrosis in a subject comprising administering a therapeutically effective amount of a small molecule BRD4 inhibitor to a subject having or at risk of developing EMT lung fibrosis. 2. The method of claim 1 , wherein the BRD4 inhibitor is administered by inhalation or instillation. 3. The method of claim 1 , wherein the BRD4 inhibitor is administered at a dose of 150 to 500 mg/day. 4. The method of claim 1 , wherein the BRD4 inhibitor is JQ1.
Assignees
Inventors
Classifications
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
- A61K31/551Primary
having two nitrogen atoms, e.g. dilazep · CPC title
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10292986B2 cover?
- Certain embodiments are directed to methods of treating chronic lung diseases in a subject comprising administering to a subject diagnosed with, exhibiting symptoms of, or at risk of developing a chronic lung disease a therapeutically effective amount of a BRD4 inhibitor or a CDK9 inhibitor to the subject.
- Who is the assignee on this patent?
- Tian Bing, Brasier Allan, Univ Texas
- What technology area does this patent fall under?
- Primary CPC classification A61K31/551. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 21 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).